Combination of dacarbazine, mitomycin C, 5-fluorouracil and vincristine in advanced colorectal cancer
β Scribed by Geoffrey Falkson; H. L. Pretorius; H. C. Falkson; H. S. Schoeman
- Publisher
- Springer
- Year
- 1983
- Tongue
- English
- Weight
- 137 KB
- Volume
- 11
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
β¦ Synopsis
Thirty patients with advanced measurable colorectal cancer received monthly courses of a combination of dacarbazine, mitomycin C, 5-fluorouracil, and vincristine (FIVMit-Or). Four of the patients had received prior chemotherapy. Two patients were not evaluable for response. Objective response was obtained in four patients. Severe toxicity was encountered in 11 patients. It is concluded that unlike the four-drug combination of 5-fluorouracil, DTIC, vincristine and BCNU (FIVB), the present regimen did not have significant antitumour activity in advanced colorectal cancer.
π SIMILAR VOLUMES
In a Phase I1 study, 50 patients with advanced breast cancer were treated with a combination of 5fluorouracil(lOO0 mg/m2 on days 1 and 2) and mitomycin C (6 mg/m2 on day 2) (FuMi regimen). The courses were repeated every third to sixth week. Although 35 patients had previously received combination c
A 55-year-old female, in which an unresectable Borrmann II-type gastric cancer (moderately differentiated adenocarcinoma) extending from vicinity of the cardia to the lower portion of the corpus, with direct invasion into the pancreas and extensive lymph node metastases, confirmed by laparotomy, was